HK1214516A1 - 局部氨苯碸和氨苯碸/阿達帕林組合物及其使用方法 - Google Patents

局部氨苯碸和氨苯碸/阿達帕林組合物及其使用方法

Info

Publication number: HK1214516A1
Authority: HK; Hong Kong
Prior art keywords: dapsone; methods; topical; adapalene; adapalene compositions
Prior art date: 2012-11-20

Application number

HK16102488.7A

Other languages

English (en)

Inventor

Kevin S Warner

Ajay P Parashar

Vijaya Swaminathan

Varsha Bhatt

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-20

Filing date

2016-03-04

Publication date

2016-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49667632&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1214516(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-04 Application filed by Allergan Inc filed Critical Allergan Inc

2016-07-29 Publication of HK1214516A1 publication Critical patent/HK1214516A1/zh

Links

MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 title 2
229960000860 dapsone Drugs 0.000 title 2
LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 title 1
229960002916 adapalene Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000000699 topical effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HK16102488.7A 2012-11-20 2016-03-04 局部氨苯碸和氨苯碸/阿達帕林組合物及其使用方法 HK1214516A1 (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261728403P	2012-11-20	2012-11-20
US201361770768P	2013-02-28	2013-02-28
PCT/US2013/070613 WO2014081674A1 (en)	2012-11-20	2013-11-18	Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Publications (1)

Publication Number	Publication Date
HK1214516A1 true HK1214516A1 (zh)	2016-07-29

Family

ID=49667632

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK16102488.7A HK1214516A1 (zh)	2012-11-20	2016-03-04	局部氨苯碸和氨苯碸/阿達帕林組合物及其使用方法

Country Status (16)

Country	Link
US (9)	US9161926B2 (zh)
EP (1)	EP2922528B1 (zh)
JP (2)	JP6285946B2 (zh)
KR (2)	KR20150085069A (zh)
CN (1)	CN105246457B (zh)
AU (2)	AU2013348247A1 (zh)
BR (1)	BR112015011673B1 (zh)
CA (1)	CA2890224C (zh)
DK (1)	DK2922528T3 (zh)
ES (1)	ES2644342T3 (zh)
HK (1)	HK1214516A1 (zh)
HU (1)	HUE035940T2 (zh)
MX (1)	MX362520B (zh)
PL (1)	PL2922528T3 (zh)
RU (1)	RU2638815C2 (zh)
WO (1)	WO2014081674A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014081674A1 (en) *	2012-11-20	2014-05-30	Allergan, Inc.	Topical dapsone and dapsone/adapalene compositions and methods for use thereof
KR20180073686A (ko) *	2015-11-04	2018-07-02	알러간, 인코포레이티드	국소 댑손 조성물을 사용하는 심상성 여드름의 치료 방법
CN105769892A (zh) *	2016-04-21	2016-07-20	蔡敏	一种治疗水痘的皮肤护理液及其制备方法
CN110430872A (zh) *	2017-02-15	2019-11-08	博塔尼克斯制药有限公司	治疗痤疮的组合物
US20180360917A1 (en) *	2017-06-15	2018-12-20	Apicore Llc	Sincalide formulations and methods of use
KR101959524B1 (ko) *	2018-09-19	2019-03-18	주식회사 우신라보타치	리도카인을 포함한 이온토포레시스용 점착성 카타플라스마 시스템
WO2022109626A1 (en) *	2020-11-23	2022-05-27	Dermavant Sciences GmbH	Gel, ointment, and foam formulations of tapinarof and methods of use
US20240108609A1 (en)	2022-09-15	2024-04-04	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3419009A1 (de)	1984-05-22	1985-11-28	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue substituierte bis(4-aminophenyl)sulfone, ihre herstellung und ihre verwendung als arzneimittel
US5532219A (en) *	1991-04-23	1996-07-02	The University Of British Columbia	Dapsone and promin for the treatment of dementia
US20030157036A1 (en)	2002-02-20	2003-08-21	Osborne David W.	Topical dapsone for the treatment of acne
US5863560A (en)	1996-09-11	1999-01-26	Virotex Corporation	Compositions and methods for topical application of therapeutic agents
US5989571A (en) *	1997-07-23	1999-11-23	Millenium Pharmaceutical Technologies, Inc.	Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US7820186B2 (en)	2001-12-21	2010-10-26	Galderma Research & Development	Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
EP1663142A2 (en)	2003-06-23	2006-06-07	MacroChem Corporation	Compositons and methods for topical administration
US20060204526A1 (en)	2003-08-13	2006-09-14	Lathrop Robert W	Emulsive composition containing Dapsone
EP1675563A4 (en) *	2003-08-13	2009-07-15	Qlt Usa Inc	EMULSION COMPOSITION WITH DAPSON
WO2006002690A1 (en) *	2004-07-07	2006-01-12	Lundbeck Pharmaceuticals Italy S.P.A.	Process for synthesis of 4-4'-diamino-diphenyl-sulfone
FR2903603B1 (fr) *	2006-07-13	2009-03-20	Galderma Res & Dev S N C Snc	Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne
EP2097075A1 (fr) *	2006-11-20	2009-09-09	Galderma Research & Development, S.N.C.	Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10.
US20090022818A1 (en)	2007-07-12	2009-01-22	Amcol International Corporation	High-foaming, viscous cleanser composition with a skin care agent
WO2009061298A1 (en) *	2007-11-07	2009-05-14	Qlt Usa, Inc.	Topical treatment with dapsone in g6pd-deficient patients
CN105287484A (zh)	2007-11-30	2016-02-03	盖尔德马研究及发展公司	含有萘甲酸衍生物、过氧化苯甲酰和成膜剂的组合物
FR2926218B1 (fr)	2008-01-10	2010-08-13	Galderma Res & Dev	Composition comprenant un retinoide et du peroxyde de benzoyle disperse.
WO2009108147A1 (en) *	2008-02-27	2009-09-03	Qlt Usa, Inc.	Dapsone to treat rosascea
US20100029781A1 (en)	2008-06-04	2010-02-04	Morris Jerome A	Methods for preparation of anti-acne formulation and compositions prepared thereby
WO2010072958A2 (fr)	2008-12-23	2010-07-01	Galderma S.A.	Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
EP2405886B8 (en) *	2009-03-11	2017-11-01	ISP Investments LLC	Topical personal care and pharmaceutical compositions and uses thereof
JP2012520267A (ja) *	2009-03-13	2012-09-06	デベヴェ・テクノロジーズ	湿疹を処置する方法
RU2012104572A (ru)	2009-07-30	2013-09-10	Аллерган, Инк.	Комбинация дапсона с адапаленом
US20110117182A1 (en)	2009-07-30	2011-05-19	Allergan, Inc.	Combination of dapsone with other anti-acne agents
WO2014081674A1 (en) *	2012-11-20	2014-05-30	Allergan, Inc.	Topical dapsone and dapsone/adapalene compositions and methods for use thereof

2013
- 2013-11-18 WO PCT/US2013/070613 patent/WO2014081674A1/en active Application Filing
- 2013-11-18 CA CA2890224A patent/CA2890224C/en active Active
- 2013-11-18 KR KR1020157016127A patent/KR20150085069A/ko active Application Filing
- 2013-11-18 EP EP13795979.7A patent/EP2922528B1/en active Active
- 2013-11-18 HU HUE13795979A patent/HUE035940T2/en unknown
- 2013-11-18 JP JP2015543097A patent/JP6285946B2/ja active Active
- 2013-11-18 KR KR1020217012602A patent/KR102291448B1/ko active IP Right Grant
- 2013-11-18 AU AU2013348247A patent/AU2013348247A1/en not_active Abandoned
- 2013-11-18 RU RU2015123207A patent/RU2638815C2/ru active
- 2013-11-18 BR BR112015011673-6A patent/BR112015011673B1/pt active IP Right Grant
- 2013-11-18 ES ES13795979.7T patent/ES2644342T3/es active Active
- 2013-11-18 MX MX2015006396A patent/MX362520B/es active IP Right Grant
- 2013-11-18 CN CN201380070519.0A patent/CN105246457B/zh active Active
- 2013-11-18 DK DK13795979.7T patent/DK2922528T3/en active
- 2013-11-18 US US14/082,955 patent/US9161926B2/en active Active
- 2013-11-18 PL PL13795979T patent/PL2922528T3/pl unknown
2015
- 2015-10-16 US US14/885,805 patent/US9517219B2/en active Active
2016
- 2016-03-04 HK HK16102488.7A patent/HK1214516A1/zh unknown
- 2016-04-27 US US15/140,109 patent/US20160243065A1/en not_active Abandoned
- 2016-12-12 US US15/376,345 patent/US20170087102A1/en not_active Abandoned
2017
- 2017-09-06 US US15/697,252 patent/US20170360729A1/en not_active Abandoned
- 2017-09-07 US US15/698,402 patent/US20170367999A1/en not_active Abandoned
2018
- 2018-02-02 JP JP2018017578A patent/JP6644817B2/ja active Active
- 2018-04-30 US US15/966,810 patent/US11273132B2/en active Active
- 2018-05-21 US US15/984,657 patent/US11116733B2/en active Active
- 2018-08-10 AU AU2018214139A patent/AU2018214139B2/en active Active
2022
- 2022-03-08 US US17/654,061 patent/US20220184002A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US11273132B2 (en)	2022-03-15
US20180263931A1 (en)	2018-09-20
US11116733B2 (en)	2021-09-14
JP2018083847A (ja)	2018-05-31
EP2922528A1 (en)	2015-09-30
RU2638815C2 (ru)	2017-12-15
BR112015011673A2 (pt)	2017-07-11
CN105246457B (zh)	2019-06-07
EP2922528B1 (en)	2017-05-31
US20160243065A1 (en)	2016-08-25
CA2890224C (en)	2021-03-09
KR102291448B1 (ko)	2021-08-18
KR20150085069A (ko)	2015-07-22
AU2018214139A1 (en)	2018-08-30
MX362520B (es)	2019-01-21
US20170360729A1 (en)	2017-12-21
US20140142184A1 (en)	2014-05-22
US20160030580A1 (en)	2016-02-04
DK2922528T3 (en)	2017-09-18
BR112015011673B1 (pt)	2021-03-09
RU2015123207A (ru)	2017-01-10
AU2018214139B2 (en)	2020-03-05
KR20210049968A (ko)	2021-05-06
US9161926B2 (en)	2015-10-20
WO2014081674A1 (en)	2014-05-30
JP6285946B2 (ja)	2018-02-28
US20170367999A1 (en)	2017-12-28
CA2890224A1 (en)	2014-05-30
US9517219B2 (en)	2016-12-13
US20220184002A1 (en)	2022-06-16
MX2015006396A (es)	2015-08-05
PL2922528T3 (pl)	2017-12-29
US20180243240A1 (en)	2018-08-30
CN105246457A (zh)	2016-01-13
HUE035940T2 (en)	2018-05-28
JP6644817B2 (ja)	2020-02-12
JP2016500072A (ja)	2016-01-07
US20170087102A1 (en)	2017-03-30
AU2013348247A1 (en)	2015-05-21
ES2644342T3 (es)	2017-11-28

Publication	Publication Date	Title
ZA201408594B (en)	2015-12-23	Xylitol-based anti-mucosal compositions and related methods and compositions
EP2729131A4 (en)	2015-01-14	TOPICAL COMPOSITIONS
HK1212898A1 (zh)	2016-06-24	酮洛芬的局部組合物
HK1214516A1 (zh)	2016-07-29	局部氨苯碸和氨苯碸/阿達帕林組合物及其使用方法
HK1212251A1 (zh)	2016-06-10	局部組合物及其使用方法
EP2823830A4 (en)	2015-11-18	MESH-HIGHNESS MEDIUM
HK1210709A1 (zh)	2016-05-06	外用組合物
HK1216250A1 (zh)	2016-10-28	'- '-羥基-二氫麥角胺化合物及組合物
GB201200707D0 (en)	2012-02-29	Composition
EP2785176A4 (en)	2015-05-06	ANTIMICROBIAL COMPOSITIONS AND RELATED METHODS
HK1202445A1 (zh)	2015-10-02	新製劑
HK1206976A1 (zh)	2016-01-22	外用劑組合物
GB201315350D0 (en)	2013-10-09	Methods and compositions
EP2878295A4 (en)	2015-12-23	COMPOSITION
GB201315347D0 (en)	2013-10-09	Methods and compositions
EP2874641A4 (en)	2016-10-12	COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
EP2837670A4 (en)	2016-01-13	COMPOSITION CONTAINING FLUOROBIPHENYL
EP2910537A4 (en)	2016-06-29	AGENT COMPOSITION GENERATING GAS
EP2910538A4 (en)	2016-06-29	AGENT COMPOSITION GENERATING GAS
GB201209597D0 (en)	2012-07-11	Composition
GB201208133D0 (en)	2012-06-20	Composition
EP2834635A4 (en)	2015-09-02	COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
EP2879652A4 (en)	2016-05-11	COMPOSITIONS AND METHODS FOR HAIR IMPROVEMENT
HUE032878T2 (hu)	2017-11-28	Bõrvédõ és bõrkiegyensúlyozó készítmény
GB201222922D0 (en)	2013-01-30	Topical formulation